American Journal of Cardiology. With the emergence of dabigatran as an option for OAC in AF patients, data on the efficacy and safety of dabigatran in comparison with warfarin in patients also receiving antiplatelet agents is needed. Plus Clopidogrel or Ticagrelor vs. Abstract Anticoagulation represents the mainstay of therapy for most patients with atrial fibrillation.
Recommended duration of triple therapy is dependent on presence or absence of ACS, risk of bleeding, and type of stent in patients treated with PCI. Results Overall, of 18 patients Mortality was also reduced, although not reaching statistical significance. Dabigatran versus warfarin in patients with atrial fibrillation.
More information about Boehringer Ingelheim can be found on www. The rates of intracranial hemorrhage did not appear to increase significantly in any group, but there were few events. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting.
Dabigatran Etexilate mg Drug: Courses were developed especially for physicians by business health experts and experienced physicians. Skip to main content. Department of Health and Human Services. The primary safety endpoint of the 30 month study is the non-inferiority in time to first major bleeding event, as defined by the International Society on Thrombosis and Haemostasis ISTHor clinically relevant non-major bleeding event.
Rates of various forms of bleeding in the 3 treatment groups warfarin, DE, and DEcomparing patients with and without concomitant antiplatelets. You are accessing a medical content website Are you a health professional? The detailed methods and main results of the RE-LY trial have been published previously.
Previous Article Vol This proportion remained fairly constant between treatment groups and between landmark periods as shown in Table 1. Larsen TB et al. June 5, Final data collection date for primary outcome measure.
The high dose of dabigatran led to a significant decrease in stroke and systemic embolism without an increase in major hemorrhage. In this trial, the use of atopaxar resulted in more minor bleeding and a trend towards fewer ischemic events.